Dynamic Homeostasis
State: Context-sensitive internal calm with predictive modulation
Key Systems: Prefrontal-limbic balance, vagal tone, GABAergic inhibition, serotonergic tuning
In this anticipatory, non-pathological state, the system maintains efficient emotional filtering, accurate bodily prediction, and low-cost arousal modulation through balanced neurocircuitry.
Mechanisms:
- Neurotransmitter Balance: Sensory and contextual inputs reaching the amygdala lead to a regulated disinhibition of local GABA(A) interneurons, enabling an appropriate level of excitatory output to signal emotional salience. This output is then modulated by top-down cortical input — particularly from the prefrontal cortex, where serotonin binds to Gq-coupled receptors (e.g., 5-HT₂C), supporting precise, proportional regulation of limbic activity. The result is balanced emotional signaling without cognitive overload.
- Balance in noradrenergic and parasympathetic tone: Absence of threat maintains quiet locus coeruleus activity, high vagal tone supports calm interoception and HRV stability
- Interoceptive stability: Interoceptive stability in the insula arises from precise glutamatergic input, GABAergic inhibition, serotonergic modulation (5-HT₁A and 5-HT₂C), and balanced autonomic signaling.
It enables the insula to compare real-time body signals against expected norms — triggering awareness or emotional response only when necessary, preserving both accuracy and calm.
Symptoms: Mild emotional reactivity, flexible worry resolution, short-term anticipatory alertness
Therapeutic Goal: Sustain coherence between emotion, body states, and prediction
Clinical Application:
- Breathing-based vagal training
- Cognitive resilience therapy
- Regular sleep/wake rhythm and light exposure
- Somatic-based practices (e.g., mindfulness, gentle yoga)
- No pharmacological treatment required
Disruption
State: Early loss of inhibitory containment and threat overcoding
Key Systems: Amygdala disinhibition, reduced GABA tone, locus coeruleus (LC) activation, insular hypervigilance
Ambiguous stimuli are now misclassified as threatening due to disinhibited sensory-affective circuits.
Disruption arises from:
- Reduced GABA(A)-mediated inhibition in the amygdala:
Interneurons fail to suppress excitatory output, allowing exaggerated limbic signaling to reach the cortex. - Impaired 5-HT₁A function in the excitatory neurons of the PFC: reduces serotonergic inhibition, leading to excessive cortical excitability. This weakens the PFC´s ability to suppress excitatory signals from limbic regions, leading to conscious overexaggeration
- Locus coeruleus → ↑ norepinephrine → cortical arousal
- BNST (Bed Nucleus of the Stria Terminalis) overactivation:
Extends and amplifies anxiety signaling under uncertainty, supporting sustained worry in place of short-term fear.
Symptoms: Excessive muscle tension, startle reflex, threat anticipation, GI dysregulation (constipation)
Therapeutic Goal: Re-stabilize inhibitory control and reduce hypervigilance
Clinical Application:
- SSRIs (e.g., Escitalopram, Paroxetine): primarily reduce prefrontal glutamatergic overactivity via 5-HT₁A activation, restoring top-down emotional regulation, though early limbic disinhibition may cause transient overstimulation.
- Buspirone (5-HT₁A partial agonist): selectively calms prefrontal tone without disinhibiting limbic GABA circuits, making it ideal for anticipatory anxiety.
- Pregabalin: modulates calcium channel activity to reduce excessive glutamate and norepinephrine release both bottom-up and top-down.
- Short-term benzodiazepines (e.g., Lorazepam, Diazepam) potentiate GABA(A) inhibition, rapidly dampening cortical arousal, though amygdala disinhibition is possible.
- Omega-3 fatty acids, polyphenol-rich diets, and stress-load reduction (sleep, circadian rhythm restoration) help restore autonomic balance and reduce interoceptive overreactivity by lowering systemic inflammatory signals that fuel sympathetic dominance.
- Cognitive therapy: Restructures maladaptive interpretations of bodily cues and ambiguous stimuli (e.g., somatic focus, “what-if” loops)
Reaction
State: Persistent arousal and somatic threat coding
Key Systems: LC-NA system, insular salience tagging, GABAergic suppression, PFC overdrive
In this phase, the system enters allostatic overload — internal and external stimuli are persistently interpreted as threatening, even without immediate danger. A breakdown in inhibitory gating and autonomic balance locks the brain-body loop into a self-reinforcing state of chronic arousal and worry.
- Low GABAergic inhibition fails to dampen emotional circuits
- Hyperactive anterior insula: misinterprets benign interoceptive signals (e.g., heart rate, tension) as threat, amplifying somatic prediction errors.
- Persistent low HRV (vagal withdrawal) → impaired top-down emotional regulation
- Sleep dysregulation and HPA axis activation
Symptoms:
- Rumination: Caused by hyperactive medial and dorsolateral PFC processing excessive bottom-up signals, leading to repetitive cognitive loops around unresolved threat.
- Restlessness & muscle tension: Sustained sympathetic arousal via LC–norepinephrine output keeps the body in a state of motor readiness.
- Avoidance: Driven by amygdala fear responses and BNST-mediated vigilance, leading to withdrawal from uncertainty.
- Sleep disruption: Elevated cortisol and circadian misalignment from HPA axis dysregulation impair sleep initiation and depth.
Therapeutic Goal: Reengage inhibition and disrupt recursive worry loops
Clinical Application:
- SNRIs (e.g., Venlafaxine, Duloxetine) for dual NA/5-HT regulation: enhance emotional regulation by increasing serotonin and norepinephrine in both prefrontal and limbic circuits. This improves top-down control and reduces somatic anxiety without directly stimulating the peripheral sympathetic system. In the prefrontal cortex, serotonin activates 5-HT₁A receptors, inhibiting overactive glutamatergic neurons and reducing excessive processing of bottom-up signals, which helps ease rumination and anticipatory anxiety. Norepinephrine, acting partly through inhibitory α2-adrenergic receptors in the amygdala, helps dampen emotional reactivity and supports more balanced limbic responses.
- Beta-blockers (e.g., Propranolol): reduce physical anxiety symptoms by blocking ß₁ receptors in the heart, lowering heart rate and dampening sympathetic arousal. This helps prevent the somatic feedback loop that can amplify cognitive anxiety, especially in situations like performance anxiety or acute stress. They target the body’s response, not the underlying emotional processing.
- GABAergic support: Short-course benzodiazepines ONLY for acute episodes (with withdrawal planning)
- CBT with exposure to worry retrains the brain to tolerate uncertainty, reducing the need for mental control or avoidance. Through repeated exposure and cognitive restructuring, it leads to enhanced prefrontal regulation, weakening the limbic overactivation that sustains generalized anxiety
- HRV biofeedback, paced breathing, and movement practices
Adaptation
State: Consolidated anxiety schema and somatic memory encoding
Key Dysfunctions: Fear generalization, interoceptive rigidity, DMN–salience system coupling
Worry becomes the brain’s default predictive framework, encoding bodily sensations as permanent threat signals.
Mechanisms:
- Amygdala–hippocampus circuits consolidate anxiety-based memory patterns
- Interoceptive signals (e.g., tension, GI changes) over-learned as threat indicators
- Default mode network over-coupled to anterior insula
- Emotional regulation strategies become rigid and avoidant
Symptoms:
- Persistent, non-triggered worry, emotional numbing, avoidance, chronic GI distress
Therapeutic Goal: Update interoceptive schemas and promote extinction learning
Clinical Application:
- CBT with interoceptive exposure
- Schema therapy to reverse encoded threat beliefs
- Low-dose DCS (D-cycloserine): a partial NMDA receptor agonist that enhances synaptic plasticity and facilitates fear extinction during exposure-based learning
- Mindfulness-based cognitive therapy (MBCT) to rewire internal attention
- Buspirone or pregabalin for patients unresponsive to SSRIs/SNRIs
- Busiprone (5-HT₁A partial agonist): initially inhibits serotonin release by stimulating presynaptic autoreceptors in the dorsal raphe nucleus, which may delay its anxiolytic effect. With chronic use, these autoreceptors desensitize, allowing serotonin levels to rise, while continued postsynaptic 5-HT₁A activation in prefrontal and limbic regions reduces glutamatergic hyperactivity and enhances emotional regulation without excessive serotonergic stimulation
- Pregabalin: binds to the α2δ subunit of voltage-gated calcium channels, reducing presynaptic glutamate and norepinephrine release in cortico-limbic circuits, thereby dampening both bottom-up somatic and top-down cognitive arousal
Refined Pathological Homeostasis
State: Low-variability anxiety state stabilized as identity
Key Dysfunctions: Default worry networks, GABAergic fatigue, cortisol flattening
The system has reorganized into a high-cost, low-flexibility mode—anxiety is now baseline, not response.
Mechanisms:
- Decreased cortisol variability → poor energetic recovery
- Low GABAergic tone → chronic arousal fatigue
- DMN dominance → internal simulations of threat maintain anxiety in absence of stimuli
- Identity-level schemas of being “worried,” “overwhelmed,” or “incapable”
Symptoms: Persistent somatic symptoms, indecisiveness, loss of confidence, anticipatory fatigue
Therapeutic Goal: Restore neurobiological variability and narrative re-integration
Clinical Application:
- Long-term maintenance pharmacotherapy (e.g., SSRIs, SNRIs, Buspirone)
- Narrative therapy, Acceptance Commitment Therapy, or Interpersonal Psychotherapy for emotional processing and identity reformation
- Psychoeducation for autonomic self-monitoring
- Gradual withdrawal of benzodiazepines if present (via taper and substitution)
- Sleep recovery strategies and long-term structure planning
Conclusion
GAD reflects not mere fear, but a disorder of persistent anticipation—where disruption is not the exception, but the baseline. Through recursive misalignment of arousal, prediction, and inhibition, GAD stabilizes into a low-variability vigilance state, often self-reinforced through interoception and cognitive schemas. Effective treatment must rephase the system—restoring inhibitory tone, reconsolidating safety, and rebuilding flexibility across mind and body.
References
Etkin, A., Prater, K. E., et al. (2009). Emotional processing in anterior cingulate and medial prefrontal cortex. American Journal of Psychiatry, 166(10), 1179–1189.
Paulus, M. P., & Stein, M. B. (2010). Interoception in anxiety and depression. Brain Structure and Function, 214(5–6), 451–463.
Sanna, E., et al. (2003). Benzodiazepine modulation of GABA<sub>A</sub> receptors in hippocampal neurons. Journal of Neuroscience, 23(36), 11711–11724.
Baldwin, D. S., et al. (2011). Evidence-based pharmacological treatment of GAD. International Journal of Neuropsychopharmacology, 14(5), 697–710.
Feltner, D. E., et al. (2011). Efficacy of pregabalin in generalized anxiety disorder. Journal of Clinical Psychopharmacology, 31(5), 565–573.
Davidson, J. R. T. (2001). Pharmacotherapy of GAD. Journal of Clinical Psychiatry, 62(Suppl 11), 46–51.
Löw, S., et al. (2023). Benzodiazepine prescribing and long-term safety concerns. Arzneimittelverordnungs-Report 2023.
Friston, K. (2010). The free-energy principle: a unified brain theory? Nature Reviews Neuroscience, 11(2), 127–138.
Thayer, J. F., et al. (2012). A meta-analysis of heart rate variability and neurovisceral integration in anxiety. Biological Psychology, 90(2), 117–126.